Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers.

Autor:	Kurose K; Department of Respiratory Medicine, Kawasaki Medical School, Okayama, Japan., Sakaeda K; Central Research Laboratories, Sysmex Corporation, Hyogo, Japan., Fukuda M; Cancer Treatment Center, Nagasaki Prefecture Shimabara Hospital, Nagasaki, Japan., Sakai Y; Central Research Laboratories, Sysmex Corporation, Hyogo, Japan., Yamaguchi H; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Takemoto S; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Shimizu K; General Thoracic Surgery, Kawasaki Medical School, Okayama, Japan., Masuda T; Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan., Nakatomi K; Department of Respiratory Medicine, NHO Ureshino Medical Center, Saga, Japan., Kawase S; Department of Respiratory Medicine, Kure Kyosai Hospital, Hiroshima, Japan., Tanaka R; Department of Dermatology, Kawasaki Medical School, Okayama, Japan., Suetsugu T; Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan., Mizuno K; Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan., Hasegawa T; Sysmex R&D Centre Europe GmbH, Hamburg, Germany., Atarashi Y; Central Research Laboratories, Sysmex Corporation, Hyogo, Japan., Irino Y; Central Research Laboratories, Sysmex Corporation, Hyogo, Japan., Sato T; Central Research Laboratories, Sysmex Corporation, Hyogo, Japan., Inoue H; Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan., Hattori N; Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan., Kanda E; Department of Medical Science, Kawasaki Medical School, Okayama, Japan., Nakata M; General Thoracic Surgery, Kawasaki Medical School, Okayama, Japan., Mukae H; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Oga T; Department of Respiratory Medicine, Kawasaki Medical School, Okayama, Japan., Oka M; Department of Immuno-Oncology, Kawasaki Medical School, Okayama, Japan. Electronic address: moom@med.kawasaki-m.ac.jp.
Jazyk:	angličtina
Zdroj:	Advances in clinical chemistry [Adv Clin Chem] 2023; Vol. 112, pp. 155-204. Date of Electronic Publication: 2022 Nov 17.
DOI:	10.1016/bs.acc.2022.09.004
Abstrakt:	Immune checkpoint inhibitors (ICI) are key drugs in systemic therapy for advanced non-small-cell lung cancer (NSCLC) and have recently been incorporated into neoadjuvant and adjuvant settings for surgical resection. Currently, ICI combinations with cytotoxic agents are frequently used in clinical practice, although several ICI clinical trials have failed to produce long-term clinical benefits. Unfortunately, clinical benefit is moderate and limited considering physical and financial burden. Therefore, selecting appropriate patients and regimens for ICI therapy is important, and biomarkers are necessary for their selection. Tumor PD-L1 expression is universally used as a biomarker; however, PD-L1 assays show low analytical validity and reproducibility due to the visual-scoring system by pathologists. Recent tumor immunology studies explore that neoantigens derived from somatic mutations and the collaboration between T and B cells efficiently elicit antitumor responses. This suggests that high tumor mutational burden and T-cell infiltration are predictive biomarkers. However, B cells producing antibody (Ab) remain poorly understood and analyzed as biomarkers. We found that NY-ESO-1 and XAGE1 of cancer-testis antigen frequently elicit spontaneous humoral and cellular immune responses in NSCLC. Serum Ab against these antigens were detected in approximately 25% of NSCLC patients and predicted ICI monotherapy responses. In addition, the Ab levels were decreased with tumor shrinkage after ICI therapy. Thus, NY-ESO-1 and XAGE1 Ab are potentially biomarkers predicting and monitoring response to ICI therapy. For clinical applications, a fully-automated assay system measuring the Ab was developed. Here, we review current ICI therapy, tumor immunology, and biomarkers in NSCLC, and discuss the applicability of the serum biomarkers NY-ESO-1 and XAGE1 Ab. Competing Interests: Declaration of competing interest The Department of Immuno-Oncology (Dr. Oka) is endowed to Kawasaki Medical School by Pole Star Co., Ltd., which does not influence the work reported in this paper. Sakaeda K, Sakai Y, Atarashi Y, Irino Y, and Sato T are employees of Sysmex Corporation. The other authors declare no financial competing interests related to this study. (Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu